Correlation Engine 2.0
Clear Search sequence regions


  • AKT (5)
  • apoptosis (4)
  • bile duct (2)
  • chir99021 (2)
  • cholangiocarcinoma (7)
  • Dox (3)
  • doxorubicin (5)
  • FAK (7)
  • gene (1)
  • glycogen (2)
  • GSK 3β (5)
  • GSK3B (1)
  • human (6)
  • indoles (2)
  • protects (1)
  • protein human (2)
  • PTK2 protein (1)
  • pyridines (2)
  • pyrimidines (2)
  • rna (3)
  • Sizes of these terms reflect their relevance to your search.

    Cholangiocarcinoma (CCA) is the most common type of malignant tumor of the bile duct and is characterized by high morbidity and mortality; it is difficult to diagnose in the early stages and responds poorly to current conventional radiotherapy and chemotherapy. The present study investigated the role of GSK‑3β signaling on the anticancer effects of doxorubicin in human CCA cells. Blocking GSK‑3β enhanced the sensitivity of human CCA cells to doxorubicin (Dox)‑induced apoptosis, which was accompanied by decreased AKT and focal adhesion kinase (FAK) activity. Moreover, inhibiting GSK‑3β using 6‑bromoindirubin‑3'‑oxime, CHIR99021 or small interfering RNA decreased phosphorylation of FAK and AKT, and promoted apoptosis of Dox‑induced human CCA cells. Moreover, FAK inhibition suppressed AKT activity independently of phosphoinositide 3‑kinase activity. These results indicated that GSK‑3β protects human CCA cells against Dox‑induced apoptosis via sustaining FAK/AKT activity.

    Citation

    Lei Li, Yuancai Xiang, Yi Zeng, Bin Xiao, Wenjing Yu, Chunyan Duan, Xianming Xia, Ting Zhang, Yongqiu Zeng, Youping Liu, Rongyang Dai. GSK‑3β inhibition promotes doxorubicin‑induced apoptosis in human cholangiocarcinoma cells via FAK/AKT inhibition. Molecular medicine reports. 2020 Nov;22(5):4432-4441

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33000181

    View Full Text